Specific Combined Therapy of Malignant Tumors with a Cytostatic and Its Modifier

Abstract

The invention relates to medicine, particularly, to treating patients with malignant tumors using the combination of cytostatic and biotherapy. Method for treating malignant hematological diseases or melanoma in subjects by applying one or more cytostatics impacting DNA in combination with N-acetyl-D-glucosaminyl-β-(1-4)-N-acetylmuramyl-L-alanyl-D-glutamic acid (GMDP-A) according to the following therapeutic sequence for subjects: Intravenous injection of ¼to ½standard therapeutic dose of the cytostatic selected for this type of subjects; Then, after cytostatic administration, the first injection of N-acetyl-D-glucosaminyl-β-(1-4)-N-acetylmuramyl-L-alanyl-D-glutamic acid (GMDP-A) in effective amount set forth for these subjects; GMDP-A repeated injections in effective amount set forth for selected subjects. Technical result of the alleged invention, which increases efficiency while treating malignant hematological diseases or melanoma, involves synergistic effect during the combined impact of a cytostatic and its immune modifier; this effect allows reduction of therapeutic dose of highly toxic cytostatics without reducing their anti-tumor effect. 1 independent claim, 3 dependent claims, 4 examples, 4 tables

Dependencies are inferred from the claim text.